BUSINESS WIRE)--Sep 19, 2018--Alector, a privately held biotechnology company pioneering immuno-neurology, a novel therapeutic approach for ... read more
Alector Initiates Phase 1 Trial of AL001 for the Treatment of Frontotemporal Dementia
Alector Initiates Phase 1 Trial of AL001 for the Treatment of Frontotemporal Dementia